Assign modules on offcanvas module position to make them visible in the sidebar.

Testimonials

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Sandro Rosell
FC Barcelona President
Wednesday, August 23, 2017

Health

As the summer sun continues to beat down on Jerusalem’s congested roadways, I am continually impressed with the runners who brave the crowds and sweltering heat day after day to get and stay in shape for the Jerusalem Marathon.  True, the race is nearly 8 months away.  But as any marathoner will tell you, the key to training is starting early, staying consistent and building upon your accomplishments one stride at a time.  

Here at ALEH’s residential facility in Jerusalem, we have used that same strategy to prepare our residents, children and young adults with severe complex disabilities, for the challenge of tackling the Jerusalem Marathon’s 800-meter ‘Community Track’ – a small step for you and me but a giant developmental leap for

One out of three may not offer the right protection, study suggests

It may be easier than ever to find sunscreen with all the right stuff, but be sure to read the label or you could still get burned.

Most sunscreens sold at major U.S. retailers and their websites now offer broad-spectrum protection, are water-resistant and have an SPF (sun protection factor) of 30 or higher as the American Academy of Dermatology (AAD) recommends, a new study found.

But more than a third of sunscreens sold by

BrainStorm Cell Therapeutics’ NurOwn platform enhances a patient's own adult stem cells to halt progression of incurable neurodegenerative diseases.

BrainStorm Cell Therapeutics of Petah Tikva is recruiting American patients for a Phase 3 clinical study of its NurOwn stem-cell treatment intended to halt progression of amyotrophic lateral sclerosis (ALS).

The announcement was made in a patient webinar last week.

The NurOwn platform grew out of a technique developed at Tel Aviv University for

Israel’s ReWalk is working with Harvard on developing an ‘exosuit’ to help MS and stroke patients regain mobility

ReWalk, the pioneering Israeli company that makes a robotic exoskeleton to get people with spinal-cord injuries on their feet, premiered the prototype for a soft suit intended to assist stroke survivors and patients suffering from multiple sclerosis regain mobility.

There are an estimated 3 million stroke survivors with lower-limb disability in the United States alone.

ReWalk’s

Israeli researchers discover that using cells from the host patient to repair tissues in the heart can be toxic

For patients with severe and end-stage heart failure there are few treatment options left apart from transplants and stem-cell therapy. But a new Israeli study finds that stem-cell therapy may harm heart-disease patients.

The research, led by Prof. Jonathan Leor of Tel Aviv University’s Sackler Faculty of Medicine and Sheba Medical Center and conducted by TAU’s Dr. Nili